What's new

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised

May 26, 2025 - 13:35
 0
Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised
Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vac...

Next Article

Product Management Service (PMS) information day 2025, Online, European Medicine...

Related Posts

EMA workshop on primary efficacy endpoints for antivirals and mAbs intended for the treatment of COVID-19 and Influenza, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 June 2025, 13:00 (CEST) to 6 June 2025, 17:00 (CEST)

EMA workshop on primary efficacy endpoints for antivira...

May 12, 2025  0

Referral: Ixchiq, Chikungunya vaccine (live) Article 20 procedures Procedure started, 12/05/2025

Referral: Ixchiq, Chikungunya vaccine (live) Article 20...

May 12, 2025  0

Summary of opinion: Tevimbra, 22/05/2025 Positive

Summary of opinion: Tevimbra, 22/05/2025 Positive

May 23, 2025  0